Sunday, February 17, 2013 Saturday, February 16, 2013 Friday, February 15, 2013- GlaxoSmithKline and Pfizer's HIV Joint Venture Gets Priority Review for Dolutegravirat Motley Fool (Fri, Feb 15)
- Better Dividend: Merck or Pfizer?at Motley Fool (Fri, Feb 15)
- Today's Dow: Pops and Dropsat Motley Fool (Fri, Feb 15)
- The Dow's Dividend Winners in 2013at Motley Fool (Fri, Feb 15)
- Agilent Misses, Guidance DisappointsZacks (Fri, Feb 15)
- Wal-Mart’s UK Arm Discovers Horse DNA and 4 Dow Movers to Followat Wall St. Cheat Sheet (Fri, Feb 15)
- Dow's Bumpy Ride Keeps It in Positive Territoryat Motley Fool (Fri, Feb 15)
- 5 Stocks Pushing The Health Care Sector Higherat TheStreet (Fri, Feb 15)
- ViiV’s HIV Treatment Dolutegravir Will Get FDA Priority Reviewat Bloomberg (Fri, Feb 15)
- The Meat and Potatoes of Abbott Labsat Motley Fool (Fri, Feb 15)
- Dow Today: Pfizer (PFE) Leads The Day Higher, Wal-Mart Stores (WMT) Lagsat TheStreet (Fri, Feb 15)
- Pfizer Inc Stock Buy Recommendation Reiterated (PFE)at TheStreet (Fri, Feb 15)
- A Golden Opportunity in the Health Trends of Boomersat Motley Fool (Fri, Feb 15)
- 5 High-Yield Blue Chips To Buy With Solid Upside Potentialat Seeking Alpha (Fri, Feb 15)
- Zoetis - Successful Offering Fails To Lift Pfizer's Sharesat Seeking Alpha (Fri, Feb 15)
Thursday, February 14, 2013Add PFE News to My Yahoo!   | |
|
0.07(0.24%) 4:00PM EDT|After Hours
:
29.02